Page 112 - 《中国药房》2025年13期

因素及预测分析[J]. 中国新药与临床杂志，2022，41 （4）：331-335.
（11）：685-690. [38] LEE J K，YOON C S，NA Y O，et al. Risk factors and
[26] VANDELLI L，MARIETTA M，TRENTI T，et al. Fibrino‐ clinical outcomes associated with acquired hypofibrino‐
gen concentrate replacement in ischemic stroke patients af‐ genemia in patients administered hemocoagulase batroxo‐
ter recombinant tissue plasminogen activator treatment[J]. bin for hemoptysis[J]. J Thorac Dis，2023，15（1）：65-76.
Adv Clin Exp Med，2019，28（2）：219-222. [39] ZOU F，WU M T，WANG Y Y. Risk factors for
[27] VANDELLI L，MARIETTA M，GAMBINI M，et al. Fi‐ hemocoagulase-associated hypofibrinogenemia in patients
brinogen decrease after intravenous thrombolysis in ische- with gastrointestinal bleeding[J]. World J Gastrointest
mic stroke patients is a risk factor for intracerebral hem- Surg，2024，16（11）：3437-3444.
orrhage[J]. J Stroke Cerebrovasc Dis，2015，24（2）： [40] MA W M，ZHAO T，YU L H，et al. Incidence，clinical fea‐
394-400. tures，and risk factors of hemocoagulase-induced hypofi‐
[28] MATOSEVIC B，KNOFLACH M，WERNER P，et al. Fi‐ brinogenemia：a retrospective real-world study[J]. Medi‐
brinogen degradation coagulopathy and bleeding compli‐ cine （Baltimore），2024，103（15）：e37773.
cations after stroke thrombolysis[J]. Neurology，2013，80 [41] HUANG M J，WANG Y P，ZHUANG W H. Clinical cha-
（13）：1216-1224. racteristics and risk factors of low fibrinogenemia induced
[29] YAN S Q，ZHANG X T，ZHANG R X，et al. Early Fi‐ by hemocoagulase[J]. Zhongguo Shi Yan Xue Ye Xue Za
brinogen depletion and symptomatic intracranial hemor‐ Zhi，2020，28（2）：583-587.
rhage after reperfusion therapy[J]. Stroke，2019，50（10）： [42] KATTULA S，BYRNES J R，WOLBERG A S. Fibrinogen
2716-2721. and fibrin in hemostasis and thrombosis[J]. Arterioscler
[30] HUANG X Y，MORETON F C，KALLADKA D，et al. Thromb Vasc Biol，2017，37（3）：e13-e21.
Coagulation and fibrinolytic activity of tenecteplase and [43] LIU J M，GAO Y. Tigecycline in the treatment of severe
pneumonia caused by Chlamydia psittaci：a case report
alteplase in acute ischemic stroke[J]. Stroke，2015，46
（12）：3543-3546. and literature review[J]. Front Med （Lausanne），2022，9：
[31] 董燕，史亚丽，苏彤，等. 抗癫痫药物治疗后发生低纤维 1040441.
蛋白原血症的临床研究[J]. 中华实用诊断与治疗杂志， [44] SALVATORE C M，TECHASAENSIRI C，TAGLIABUE
2023，37（5）：480-485. C，et al. Tigecycline therapy significantly reduces the con‐
[32] BUZZATTI E，FORGHIERI F，PATERNO G，et al. In centrations of inflammatory pulmonary cytokines and che‐
BCR-ABL1 positive B-cell acute lymphoblastic leukemia， mokines in a murine model of Mycoplasma pneumoniae
pneumonia[J]. Antimicrob Agents Chemother，2009，53
steroid therapy induces hypofibrinogenemia[J]. J Clin
Med，2022，11（7）：1776. （4）：1546-1551.
[33] SCIUMÈ M，FRACCHIOLLA N S，CORTELEZZI A. Se‐ [45] HAKEAM H A，AL DUHAILIB Z，SALAHUDDIN N，
vere hypofibrinogenemia associated with imatinib and et al. Impact of tigecycline versus imipenem-cilastatin on
fibrinogen levels following cytoreductive surgery （CRS）
prednisone therapy in Philadelphia chromosome-positive and hyperthermic intraperitoneal chemotherapy （HIPEC）：
acute lymphoblastic leukemia[J]. Leuk Lymphoma，2018， a randomized-controlled study[J]. J Chemother，2018，30
59（10）：2516-2517. （4）：224-232.
[34] ALDOSS I，DAN D E，BEHRENDT C E，et al. Toxicity [46] RAUSCH E，VEMURI K，ANDERMAN T M，et al.
profile of repeated doses of PEG-asparaginase incorpo‐ Eravacycline associated hypofibrinogenemia：a case series
rated into a pediatric-type regimen for adult acute lympho‐ of transplant patients with Mycobacterium abscessus in‐
blastic leukemia[J]. Eur J Haematol，2016，96（4）： fections and review of literature[J]. Open Forum Infect
375-380. Dis，2022，9（12）：ofac591.
[35] HUNAULT-BERGER M，CHEVALLIER P，DELAIN M， [47] MORRISETTE T，ALOSAIMY S，PHILLEY J V，et al.
et al. Changes in antithrombin and fibrinogen levels du- Preliminary，real-world，multicenter experience with oma‐
ring induction chemotherapy with L-asparaginase in adult
dacycline for Mycobacterium abscessus infections[J].
patients with acute lymphoblastic leukemia or lymphoblas‐ Open Forum Infect Dis，2021，8（2）：ofab002.
tic lymphoma. Use of supportive coagulation therapy and [48] YANG X X，JIN L，LUO X M，et al. Serum concentration
clinical outcome：the CAPELAL study[J]. Haematologica， as a predictor of tigecycline-induced hypofibrinogenemia
2008，93（10）：1488-1494. in critically ill patients：a retrospective cohort study[J]. Int
[36] ORVAIN C，BALSAT M，TAVERNIER E，et al. Throm- J Infect Dis，2022，123：136-142.
boembolism prophylaxis in adult patients with acute lym‐ [49] YANG X X，JIN L，LUO X M，et al. Pharmacokinetic/
phoblastic leukemia treated in the GRAALL-2005 study pharmacodynamic target attainment of tigecycline in pa‐
[J]. Blood，2020，136（3）：328-338. tients with hepatic impairment in a real-world setting[J].
[37] BEINART G，DAMON L. Thrombosis associated with L- Ther Drug Monit，2023，45（6）：786-791.
asparaginase therapy and low fibrinogen levels in adult （收稿日期：2025-02-18 修回日期：2025-05-20）
acute lymphoblastic leukemia[J]. Am J Hematol，2004，77 （编辑：胡晓霖）

· 1654 · China Pharmacy 2025 Vol. 36 No. 13 中国药房 2025年第36卷第13期